Efficacy of Three Novel Compounds on Cell Viability.
Sutherland, Sydney Anne, Chad Stephens, Elizabeth H. Forrester

Triple-negative breast cancer is a form of breast cancer which accounts for 10-20% of breast cancer diagnoses in which the receptors for progesterone, estrogen, and epidermal growth factor receptor 2 (HER-2), are not present. Due to their absence, drugs that target these receptors, such as Tamoxifen, Megace and Herceptin, are ineffective. Chemotherapy may be an effective treatment, especially in early stages, but its side effects are often painful and demoralizing. These studies focus on analyzing the efficacy of three novel compounds, CES-X-29D, CES-I-61, and ACB-111-163, on the proliferation and viability of various triple-negative metastatic breast cancer cell lines. Two lines, MDA-MB-231 and MDA-MB-468, are human in origin, while the other line, MMTV-PyVMT, is murine. Results from various experiments indicate ACB-111-163 and CES-I-61 decrease cell viability. In the future, we aim to determine the effect of these compounds on the epithelial-mesenchymal transition (EMT), which is an early indicator of invasion and metastasis.

Click here to view poster

More Research Highlights